Capital World Investors Buys 100,000 Shares of Ralliant Corporation $RAL

Capital World Investors boosted its stake in Ralliant Corporation (NYSE:RAL) by 6.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,652,364 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Capital World Investors’ holdings in Ralliant were worth $84,122,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in RAL. Danske Bank A S bought a new stake in Ralliant in the fourth quarter valued at $25,000. V Square Quantitative Management LLC bought a new stake in Ralliant in the fourth quarter valued at $26,000. Allworth Financial LP boosted its holdings in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant in the third quarter valued at $26,000. Finally, BOKF NA bought a new stake in Ralliant in the third quarter valued at $29,000.

Ralliant Price Performance

RAL opened at $63.66 on Wednesday. The stock has a 50-day moving average price of $51.63 and a 200-day moving average price of $49.45. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The firm has a market cap of $7.13 billion and a PE ratio of -5.82. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $64.16.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Sell-side analysts predict that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Analyst Ratings Changes

Several research firms recently weighed in on RAL. Barclays lifted their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Truist Financial reissued a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Evercore assumed coverage on shares of Ralliant in a report on Tuesday. They set an “outperform” rating and a $80.00 target price on the stock. Finally, Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a report on Wednesday, May 27th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $67.30.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.